Newcourt Acquisition Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Marc Balkin

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.8yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.3yrs

Recent management updates

Recent updates

CEO

Marc Balkin (49 yo)

2.8yrs

Tenure

Mr. Marc Gregory Balkin has been Chief Executive Officer and Director at Newcourt Acquisition Corp since March 2021. Mr. Balkin founded of Balkin and Co in 2015. He was a Partner at Hasso Plattner Ventures...

Board Members

Name	Position	Tenure	Compensation	Ownership
Marc Balkin	CEO & Director	2.8yrs	no data	no data
Ryan Gilbert	Member of Advisory Board	no data	no data	no data
Michael Jordaan	Chairman of the Board	2.8yrs	no data	no data
Rohit Bodas	Independent Director	2.3yrs	no data	no data
Simran Aggarwal	Independent Director	2.3yrs	no data	no data
Nicole Farb	Independent Director	2.3yrs	no data	no data

2.3yrs

Average Tenure

48.5yo

Average Age

Experienced Board: NCAC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Newcourt Acquisition Management

Management criteria checks 0/4

Key information

Recent management updates

Newcourt Acquisition Corp Announces Resignation of Daniel Rogers as Daniel Rogers

Recent updates

Newcourt Acquisition Files Form 15

Newcourt Acquisition's Ordinary Shares, Units to Be Delisted and Deregistered Under Section 12(b) of the Exchange Act

Psyence Therapeutics Corp. completed the acquisition of Newcourt Acquisition Corp (NasdaqGM:NCAC) from Newcourt SPAC Sponsor LLC, Polar Asset Management Partners Inc. and others in a reverse merger transaction.

Newcourt Acquisition Corp announced that it expects to receive $10 million in funding from Psyence Therapeutics Corp.

Newcourt Acquisition Corp announced delayed 10-Q filing

Newcourt Acquisition Regains Compliance with the Market Value of Listed Securities Rule

Newcourt Acquisition Receives Non-Compliance Notice From Nasdaq

Newcourt Acquisition Receives Non-Compliance Notice From Nasdaq

Newcourt Acquisition Corp announced that it expects to receive $0.75 million in funding from Newcourt SPAC Sponsor LLC

Newcourt Acquisition Corp Announces Resignation of Daniel Rogers as Daniel Rogers

Psyence Therapeutics Corp. entered into a definitive business combination agreement to acquire Newcourt Acquisition Corp (NasdaqGM:NCAC) from Newcourt SPAC Sponsor LLC and others for $50 million in a reverse merger transaction.

Newcourt Acquisition Corp announced delayed annual 10-K filing

CEO

Tenure

Board Members

Average Tenure

Average Age